Dicot Pharma ABFRA:KN0 -2.21%23 Current Ratio is 5.72 as of Mar. 2026, which is 36% below its 10-year median of 8.91. GuruFocus rates FRA:KN0 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 997 Drug Manufacturers companies, Dicot Pharma AB ranks better than 88.77% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Dicot Pharma AB's current ratio for the quarter that ended in Mar. 2026 was 5.72.
Dicot Pharma AB has a current ratio of 5.72. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Dicot Pharma AB's Current Ratio or its related term are showing as below:
FRA:KN0'
s Current Ratio Range Over the Past 10 Years
Min: 0.87 Med: 8.91 Max: 16.76
Current: 5.72
During the past 9 years, Dicot Pharma AB's highest Current Ratio was 16.76. The lowest was 0.87. And the median was 8.91.
FRA:KN0's Current Ratio is ranked better than 88.77% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:KN0: 5.72
Dicot Pharma AB (FRA:KN0) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Dicot Pharma AB Current Ratio Related Terms
Dicot Pharma AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Dicot Pharma AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dicot Pharma AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dicot Pharma AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dicot Pharma AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Dicot Pharma AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dicot Pharma AB (FRA:KN0) has a Current Ratio of 5.72 as of Mar. 2026. This is 36% below median its historical median of 8.91. Over the past decade, Dicot Pharma AB's Current Ratio has ranged from 0.87 to 16.76. According to the industry distribution chart, Dicot Pharma AB ranks #112 out of 997 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is Dicot Pharma AB's Current Ratio too high?
Dicot Pharma AB's current Current Ratio of 5.72 is 36% below median its 10-year median of 8.91. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 16.76. The Drug Manufacturers industry median Current Ratio is 2.00. Dicot Pharma AB's value of 5.72 is 186% above this industry median. Based on the distribution chart, Dicot Pharma AB ranks #112 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dicot Pharma AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Dicot Pharma AB's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dicot Pharma AB ranks #112 out of 997 companies for Current Ratio. This places Dicot Pharma AB in the top 11% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Dicot Pharma AB's value of 5.72 is 186% above this benchmark. Historically, Dicot Pharma AB's own Current Ratio has ranged from 0.87 to 16.76 over the past decade. While the company's 10-year median is 8.91 vs. the industry median of 2.00, Dicot Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dicot Pharma AB's current Current Ratio of 5.72 is 186% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dicot Pharma AB's current Current Ratio is 5.72, which is 36% below median its own 10-year median of 8.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dicot Pharma AB stock overvalued right now?
Dicot Pharma AB (FRA:KN0) has a current Current Ratio of 5.72. The current Current Ratio is 5.72, which is 36% below median its 10-year median of 8.91 and 186% above the Drug Manufacturers industry median of 2.00. Dicot Pharma AB's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Dicot Pharma AB (FRA:KN0), the current Current Ratio is 5.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation than existing preparations. The business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects, and is also used in the treatment of erectile dysfunction and premature ejaculation.
23GF Score
Get the complete analysis for FRA:KN0
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN0 has been successfully added to your 
